• ERT and Bioclinica are now Clario. Find out more about our new name, and why we have come together.

Your using an unsupported browser. Please update to a modern browser for a better experience.

ERS International Congress

September 4, 2022
September 6, 2022
CET
Fira Gran Via Carrer de l'Alumini, Hall 8, s/n, 08908 Barcelona, Spain

The ERS Congress is the once-a-year occasion when the world’s respiratory experts come together, to present and discuss the latest scientific and clinical advances across the entire field of respiratory medicine. The reputation of ERS derives from the outstanding scientific program of their congress, which is now the largest respiratory meeting in the world. ERS is one of the leading medical organizations in the respiratory field, with a growing membership spanning over 160 countries. ERS prioritizes science, education and advocacy in order to promote lung health, alleviate suffering from disease and drive standards for respiratory medicine globally.

Stop by our booth K.05 and talk to our experts about what’s new at Clario!

Session Information:

Title: Adopting the 2019 ATS/ERS spirometry guidelines in clinical trials: impact on site and patient burden

Date: Monday, September 5th, 2022

Time: 9:00 a.m. CET

2019 ATS/ERS spirometry guidelines (GL) introduced a 4th phase that allows objective determination of full inflation. Adoption of the 2019 GL by pulmonary labs has been slow. We evaluate the impact of 2019 GL on site and patient burden in clinical trials.This poster presentation will review the methods, results and conclusions from the evaluation of this impact.

Presenter

Phil Lake headshot

Phil Lake, PhD

Senior Director, Respiratory Solutions at Clario

Phil Lake is a respiratory specialist who supports clients all around the world and has held various roles in drug development for more than 22 years, predominantly focused on respiratory trials. Previously, he held positions at SmithKline Beecham and GlaxoSmithKline within respiratory drug development, working on respiratory drug development in a range of drug mechanisms and trial designs including landmark studies such as exacerbations, mortality, and mechanistic studies focusing on biopsy and sputum biomarkers. Phil has concentrated extensively on understanding drivers for variability to reduce the risk of study failure that included traditional respiratory indications as well as generic bioequivalence studies and the use of lung function as a biomarker within many rare diseases. He has focused on understanding potential safety signals within drugs which could have negative impacts on lung health. Phil has been pivotal in early centralized over read studies and is committed to driving improvements in lung function testing within decentralized trials.